Skip to main content

Commercial genomics

Inquiry

Genomic testing seeks to offer health benefits and can provide other useful services. However, some have raised concerns regarding the potential risks associated with genomic tests being made directly available to consumers, including on the tests’ reliability and accuracy, the support available to consumers for understanding and acting on results, and the impact of these commercial tests on the NHS.

This inquiry builds upon our predecessor Committee’s inquiry, and will make use of evidence submitted to that inquiry. Please only submit new evidence if you want to update or supplement information that the previous Committee had received, or to provide specific evidence on the ‘in-vitro diagnostic medical device’ regulation.

Read the call for evidence for more information about this inquiry.

Reports, special reports and government responses

View all reports and responses
First Report - Direct-to-consumer genomic testing
Inquiry Commercial genomics
HC 94
Report
Response to this report
First Special Report - Direct-to-consumer genomic testing: Government Response to the Committee’s First Report
HC 805
Special Report
First Special Report - Direct-to-consumer genomic testing: Government Response to the Committee’s First Report
Inquiry Commercial genomics
HC 805
Special Report
Correspondence from Kathy Hibbs, Chief Legal and Regulatory Officer, 23andMe, relating to Commercial genomics follow-up
Inquiry Commercial genomics
Correspondence
Correspondence from • Avi Lasarow, Chief Executive Officer, DNAfit, relating to Commercial genomics follow-up
Inquiry Commercial genomics
Correspondence
Correspondence from • Carla Newell, Chief Legal Officer, Ancestry, relating to Commercial genomics follow-up
Inquiry Commercial genomics
Correspondence

Oral evidence transcripts

View all oral evidence transcripts
17 June 2020
Inquiry Commercial genomics
Witnesses Dr Tara Clancy (Council Member at Nuffield Council on Bioethics), Graeme Tunbridge (Director of Devices at Medicines and Healthcare products Regulatory Agency), Lord Bethell (Minister for Innovation at Department of Health and Social Care), and Professor Sir Mark Caulfield (Chief Scientist at Genomics England)
Oral Evidence
Lord Bethell (Parliamentary Under Secretary of State for Innovation (Lords) at Department for Health and Social Care) (COG0009)
UKCloud Ltd (COG0008)
Dr Yiannis Mavrommatis (Programme Director MSc Nutrition and Genetics at St Mary's University) (COG0007)

Other publications

No other publications published.

Contact us

We can’t usually help you with an individual problem or a specific complaint.

  • Email: commonssitc@parliament.uk
  • Phone: 020 7219 5023 (general enquiries) |020 7219 0731 (media enquiries)
  • Address: Science, Innovation and Technology Committee, House of Commons, London, SW1A 0AA